VerifyMe (VRME) 10-Q 19 Aug 14 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Jun. 30, 2014	Aug. 19, 2014
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'LASERLOCK TECHNOLOGIES INC	'
Entity Central Index Key	'0001104038	'
Trading Symbol	'llti	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	307,578,149
Document Type	'10-Q	'
Document Period End Date	30-Jun-14	'
Amendment Flag	'false	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Jun. 30, 2014	Dec. 31, 2013
CURRENT ASSETS	'	'
Cash and cash equivalents	$107,770	$1,285,973
Accounts receivable, net of allowance of $0 at June 30, 2014 and December 31, 2013	58,721	3,573
Inventory	84,283	34,271
Prepaid expenses	184,210	189,474
TOTAL CURRENT ASSETS	434,984	1,513,291
PROPERTY AND EQUIPMENT	'	'
Capital equipment, net of accumulated depreciation of $126,579 and $91,952 as of June 30, 2014 and December 31, 2013	109,448	144,074
OTHER ASSETS	'	'
Deposits	37,197	37,197
Patents and trademarks, net of accumulated amortization of $111,948 and $105,393 as of June 30, 2014 and December 31, 2013	114,141	120,695
TOTAL ASSETS	695,770	1,815,257
CURRENT LIABILITIES	'	'
Accounts payable and accrued expenses	409,439	316,784
Accrued interest - related party	19,763	16,668
Embedded derivative liability	200,000	800,000
Notes payable - net of accumulated discount of $26,617 as of June 30, 2014	273,383	50,000
TOTAL CURRENT LIABILITIES	902,585	1,183,452
LONG-TERM LIABILITIES	'	'
Warrant liability	3,641,650	6,000,000
Accrued interest - related parties	105,665	300,677
Senior secured convertible notes payable - related parties	114,000	330,249
TOTAL LONG-TERM LIABILITIES	3,861,315	6,630,926
STOCKHOLDERS' DEFICIT	'	'
Convertible Preferred Stock, $ .001 par value; 75,000,000 shares authorized; 21,111,111 shares issued and outstanding as of June 30, 2014 and December 31, 2013	633,333	633,333
Common stock, $ .001 par value; 675,000,000 shares authorized; 337,374,052 shares issued and 307,578,149 outstanding at June 30, 2014 and 319,862,042 shares issued and 290,066,139 outstanding at December 31, 2013	337,374	319,862
Additional paid in capital	24,630,326	22,938,983
Treasury stock, at cost (29,795,903 shares at June 30, 2014 and December 31, 2013)	-113,389	-113,389
Accumulated deficit	-29,555,774	-29,777,910
STOCKHOLDERS' DEFICIT	-4,068,130	-5,999,121
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$695,770	$1,815,257

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parentheticals) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Statement Of Financial Position [Abstract]	'	'
Allowance for accounts receivable (in dollars)	$0	$0
Accumulated depreciation on capital equipment (in dollars)	126,579	91,952
Accumulated amortization, patent and trademarks (in dollars)	111,948	105,393
Discount, notes payable (in dollars)	$26,617	'
Convertible preferred stock, par value (in dollars per share)	$0.00	$0.00
Convertible preferred stock, shares authorized	75,000,000	75,000,000
Convertible preferred stock, shares issued	21,111,111	21,111,111
Convertible preferred stock, shares outstanding	21,111,111	21,111,111
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	675,000,000	675,000,000
Common stock, shares issued	337,374,052	319,862,042
Common stock, shares outstanding	307,578,149	290,066,139
Treasury stock, shares	29,795,903	29,795,903

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended				6 Months Ended
	Jun. 30, 2014		Jun. 30, 2013		Jun. 30, 2014		Jun. 30, 2013
NET REVENUES	'		'		'		'
Sales	$65,148		'		$65,148		$3,140
Royalties	'		'		'		'
TOTAL NET REVENUE	65,148		'		65,148		3,140
COST OF SALES	54,440		'		54,440		2,710
GROSS PROFIT	10,708		'		10,708		430
OPERATING EXPENSES	'		'		'		'
General and administrative	180,820		170,699		305,581		231,859
Legal and accounting	178,302		55,651		310,497		177,580
Patent costs	'		'		'		'
Payroll expenses (a)	427,178	[1]	8,204,468	[1]	1,501,858	[1]	8,952,497	[1]
Research and development (b)	30,120	[2]	162,819	[2]	875,849	[2]	137,424	[2]
Sales and marketing	73,895		52,197		125,331		95,006
Total operating expenses	890,315		8,645,834		3,119,116		9,594,366
LOSS BEFORE OTHER INCOME (EXPENSE)	-879,607		-8,645,834		-3,108,408		-9,593,936
OTHER INCOME (EXPENSE)	'		'		'		'
Interest income	'		1		'		1
Interest expense	-13,121		-32,978		-24,028		-74,219
Loss on extinguishment of debt	-82,000		-1,221,875		-82,000		-1,221,875
Change in fair value of warrants	3,726,572		-858,864		2,836,572		-12,780,374
Change in fair value of embedded derivative liability	900,000		'		600,000		'
Fair value of warrants in excess of consideration for convertible preferred stock	'		'		'		-2,995,791
TOTAL OTHER INCOME (EXPENSE)	4,531,451		-2,113,716		3,330,544		-17,072,258
NET INCOME (LOSS) BEFORE INCOME TAX BENEFIT	3,651,844		-10,759,550		222,136		-26,666,194
INCOME TAX BENEFIT	'		'		'		'
NET INCOME (LOSS)	3,651,844		-10,759,550		222,136		-26,666,194
Less: Deemed dividend distribution	'		'		'		-1,000,000
NET INCOME (LOSS) APPLICABLE TO COMMON STOCKHOLDERS	$3,651,844		($10,759,550)		$222,136		($27,666,194)
NET INCOME (LOSS) PER COMMON SHARE	'		'		'		'
BASIC (in dollars per share)	$0.01		($0.04)		$0		($0.11)
DILUTED (in dollars per share)	$0.01		($0.04)		$0		($0.11)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING	'		'		'		'
BASIC (in shares)	302,039,675		240,935,887		299,856,170		233,374,035
DILUTED (in shares)	323,600,786		240,935,887		321,417,281		233,374,035
[1]	Includes share based compensation of $61,312 and $802,267 for the three and six months ended June 30, 2014 and $7,939,629 and $8,272,227 for the three and six months ended June 30, 2013.
[2]	Includes share based compensation of $400,000 for the six months ended June 30, 2014 related to the Patent and Technology License Agreement.

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Operations (Unaudited) (Parentheticals) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014
	Payroll expenses	Payroll expenses	Payroll expenses	Payroll expenses	Research and development
Share based compensation	$61,312	$7,939,629	$802,267	$8,272,227	$400,000

Condensed_Consolidated_Stateme2

Condensed Consolidated Statement of Changes in Stockholders' Deficit (USD $)	Convertible Preferred Stock	Common Stock	Deferred Consulting Fees	Additional Paid-In Capital	Treasury Stock	Deficit Accumulated During the Development Stage	Total
Balance at Dec. 31, 2013	$633,333	$319,862	'	$22,938,983	($113,389)	($29,777,910)	($5,999,121)
Balance (in shares) at Dec. 31, 2013	21,111,111	290,066,139	'	'	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'	'	'
Issuance of shares of common stock for services	'	6,349	'	393,651	'	'	400,000
Issuance of shares of common stock for services (in shares)	'	6,349,206	'	'	'	'	'
Cashless exercise of options	'	2,714	'	-2,714	'	'	'
Cashless exercise of options (in shares)	'	2,714,285	'	'	'	'	'
Fair value of employee stock options	'	'	'	802,267	'	'	802,267
Fair value of employee stock options (in shares)	'	'	'	'	'	'	'
Issuance of common stock for settlement of debt	'	8,449	'	498,139	'	'	506,588
Issuance of common stock for settlement of debt (in shares)	'	8,448,519	'	'	'	'	'
Net Income	'	'	'	'	'	222,136	222,136
Balance at Jun. 30, 2014	$633,333	$337,374	'	$24,630,326	($113,389)	($29,555,774)	($4,068,130)
Balance (in shares) at Jun. 30, 2014	21,111,111	307,578,149	'	'	'	'	'

Condensed_Consolidated_Stateme3

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
CASH FLOWS FROM OPERATING ACTIVITIES	'	'
Net Income (loss)	$222,136	($26,666,194)
Adjustments to reconcile net income (loss) to net cash used in operating activities	'	'
Fair value of options issued in exchange for services	802,267	8,272,227
Accretion of discount on notes payable	'	2,478
Change in fair value warrant liability	-2,836,572	12,780,374
Change in fair value embedded derivative liability	-600,000	'
Fair value of warrants in excess of consideration for convertible preferred stock	'	2,995,791
Fair value of stock in excess of converted notes payable and accrued interest	82,000	1,221,875
Amortization and depreciation	41,180	40,749
Stock & warrants issued in exchange for services	844,000	'
(Increase) decrease in assets	'	'
Accounts receivable	-55,148	-3,140
Inventory	-50,013	-19,454
Prepaid expenses	5,263	280,263
Deposit	'	-37,197
Increase (decrease) in liabilities	'	'
Accounts payable and accrued expenses	116,684	-220,674
Net cash used in operating activities	-1,428,203	-1,352,902
CASH FLOWS FROM INVESTING ACTIVITIES	'	'
Purchase of property and equipment	'	-10,573
Purchase of patents and trademarks	'	-21,954
Net cash used in investing activities	'	-32,527
CASH FLOWS FROM FINANCING ACTIVITIES	'	'
Proceeds from issuance of preferred stock	'	1,000,000
Proceeds from issuance of common stock	'	235,000
Proceeds from exercise of stock options	'	17,919
Proceeds from exercise of warrants	'	10,000
Proceeds from issuance of notes payable	250,000	'
Net cash provided by financing activities	250,000	1,262,919
NET DECREASE IN CASH AND CASH EQUIVALENTS	-1,178,203	-122,510
CASH AND CASH EQUIVALENTS - BEGINNING OF YEAR	1,285,973	2,994,350
CASH AND CASH EQUIVALENTS - END OF PERIOD	107,770	2,871,840
Cash paid during the year for:	'	'
Interest	'	13,896
Income taxes	'	'
Fair value of stock issued for conversion of notes payable and accrued interest	424,588	668,125
Accretion of discount on preferred stock as deemed dividend distribution	'	1,000,000
Fair value of beneficial conversion feature	'	1,000,000
Fair value of warrants issued as debt discount	$34,222	'

SUMMARY_OF_SIGNIFICANT_ACCOUNT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	'
	NOTE 1 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Nature of the Business
	LaserLock Technologies Inc., together with its wholly-owned subsidiary, LL Security Products, Inc., is referred to as the “Company.” LaserLock Technologies Inc. was incorporated in the State of Nevada on November 10, 1999. The Company is based in Washington, D.C. And is publicly traded on the OTC Market under the ticker symbol “LLTI”. A high-tech solutions company in the field of authenticating people and products, LaserLock offers state-of-the-art solutions to combat identity fraud and counterfeiting utilizing multi-factor authentication and a suite of security pigments for governments, health care providers, the gaming industry, the financial services industry and high-end retailers.
	The Company invests in developing new proprietary color shifting inks that it believes will allow it to penetrate broader markets and result in increased revenues. The Company refines its technologies and their applications, and now has what it believes to be one of the most cost effective and efficient authentication technologies available. Its most recent technology takes advantage of the new ubiquitous energy efficient fluorescent lighting to change the color of ink, resulting in numerous potential new applications ranging from credit cards to drivers licenses, passports, stock certificates, clothing labels, currency, ID cards, and tax stamps. The technologies can also be used to protect DVDs, apparel, pharmaceuticals, and virtually any other physical product.
	The Company’s digital solution is a multi-platform (iOS and Android) strong authentication solution that integrates biometrics and geo-location tagging. The solution completely eliminates passwords and the inherently weak security they provide. The solution also removes the user complexity associated with having to manage many complex passwords. The solution can be delivered either as a high availability cloud service, managed by LaserLock, or as licensed software product for operation on the client’s premises.
	The solution integrates three independent authentication factors – something you have (for instance a smartphone), something you know (for instance a color gesture swipe) and something you are (for instance your facial geometry) - into a simple, fast, intuitive solution. The system can also accurately determine the precise location of the individual using a variety of mechanisms including GPS, cell tower triangulation, IP or WIFI address. Because the solution incorporates biometrics it completely eliminates the possibility that users might share their authentication credentials. The combination of biometrics and geolocation provides extremely strong transactional evidence, making it nearly impossible for a end-user to refute having been part of a transaction.
	The Company’s activities are subject to significant risks and uncertainties, including the need to secure additional funding to operationalize the Company’s current technology.
	Basis of Presentation
	The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions for Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The accompanying unaudited consolidated financial statements should be read in conjunction with the financial statements and notes included in the Company’s Annual Report on form 10-K for the year ended December 31, 2013 as filed with the Securities and Exchange Commission (the “SEC”). Operating results for the three and six months ended June 30, 2014 are not necessarily indicative of the results that may be expected for the year ending December 31, 2014.
	Principle of Consolidation
	The accompanying condensed consolidated financial statements include the accounts of LaserLock Technologies Inc. and its wholly-owned subsidiary, LL Security Products, Inc. All inter-company transactions have been eliminated in consolidation.
	Use of Estimates
	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.
	Comprehensive Income
	The Company follows Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 220 in reporting comprehensive income. Comprehensive income is a more inclusive financial reporting methodology that involves disclosure of certain financial information that historically has not been recognized in the calculation of net income. Since the Company has no items of other comprehensive income (loss), comprehensive income (loss) is equal to net income (loss).
	Fair Value of Financial Instruments
	The Company’s financial instruments consist of cash, accounts receivable, accounts payable and accrued expenses, embedded derivative, warrant liability and notes payable. The carrying value of cash, accounts receivable, accounts payable and accrued expenses approximate their fair value because of their short maturities. The Company believes the carrying amount of its notes payable and convertible debt approximates its fair value based on rates and other terms currently available to the Company for similar debt instruments.
	Cash and Cash Equivalents
	For purposes of reporting cash flows, the Company considers all cash accounts, which are not subject to withdrawal restrictions or penalties, and certificates of deposit and commercial paper with original maturities of 90 days or less to be cash or cash equivalents.
	Concentration of Credit Risk Involving Cash and Cash Equivalents
	The Company’s cash and cash equivalents are held at two financial institutions. At times, the Company’s deposits may exceed Federal Deposit Insurance Corporation (FDIC) coverage limits. The Company has not experienced any losses from maintaining cash accounts in excess of federally insured limits.
	Inventory
	Inventory principally consists of penlights and pigments and is stated at the lower of cost (determined by the first-in, first-out method) or market.
	Property and Equipment
	Property and equipment is stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, principally five to seven years. Maintenance and repairs of property are charged to operations, and major improvements are capitalized. Upon retirement, sale, or other disposition of property and equipment, the costs and accumulated depreciation are eliminated from the accounts, and any resulting gain or loss is included in operations. Depreciation of property and equipment was $17,313 and $34,627 for the three and six months ended June 30, 2014 and $33,900 and $34,212 for the three and six months ended June 30, 2013.
	Patents and Trademark
	The Company has five issued patents, filed for three provisional patents for anti-counterfeiting technology and purchased a trademark. Costs associated with the registration and legal defense of the patents have been capitalized and are amortized on a straight-line basis over the estimated lives of the patents that were determined to be17 to 20 years.
	Long-Lived Assets
	The Company evaluates the recoverability of its long-lived assets in accordance with ASC 360 “Property, Plant, and Equipment.” The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets is measured by a comparison of the carrying amount of an asset to future cash flows expected to be generated by the asset, undiscounted and without interest or independent appraisals. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the assets.
	Deferred Financing Costs
	Costs incurred in securing long-term debt are deferred and amortized, as a charge to interest expense, over the term of the related debt. In the case of long-term debt modifications, the Company follows the guidance provided by ASC 470-50 “Debt – Modification and Extinguishments.”
	Convertible Notes Payable
	Convertible notes payable, for which the embedded conversion feature does not qualify for derivative treatment, are evaluated to determine if the effective or actual rate of conversion per the terms of the convertible note agreement is below market value. In these instances, the Company accounts for the value of the beneficial conversion feature (BCF) as a debt discount, which is then accreted to interest expense over the life of the related debt using the straight-line method, which approximates the effective interest method.
	Derivative Instruments
	The Company evaluates its convertible debt, warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with Topic 480 of the FASB ASC and Topic 815 of the FASB Accounting Standards Codification. The result of this accounting treatment is that the fair value of the embedded derivative if required to be bifurcated is marked-to-market at each balance sheet date and recorded as a liability. The change in fair value is recorded in the Statement of Operations as a component of other income or expense. Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity.
	In circumstances where the embedded conversion option in a convertible instrument is required to be bifurcated and there are also other embedded derivative instruments in the convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument.
	The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Equity instruments that are initially classified as equity that become subject to reclassification are reclassified to liability at the fair value of the instrument on the reclassification date. Derivative instrument liabilities will be classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is expected within 12 months of the balance sheet date.
	Revenue Recognition
	In accordance with SEC Staff Accounting Bulletin No. 104, Revenue Recognition (Codified in FASB ASC 605), the Company recognizes revenue when (i) persuasive evidence of a customer or distributor arrangement exists, (ii) a retailer, distributor or wholesaler receives the goods and acceptance occurs, (iii) the price is fixed or determinable, and (iv) collectability of the revenue is reasonably assured. Subject to these criteria, the Company recognizes revenue from product sales, consisting mainly of pigments and penlights, upon shipment to the customer. Royalty revenue is recognized upon receipt of notification from a customer that the Company’s product has been used in the customer’s production process.
	Income Taxes
	The Company follows FASB ASC 740 when accounting for income taxes, which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed annually for temporary differences between the financial statements and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Income tax expense is the tax payable or refundable for the period plus or minus the change during the period in deferred tax assets and liabilities.
	Stock-based Payments
	The Company accounts for stock-based compensation under the provisions of ASC 718, Compensation—Stock Compensation, which requires the measurement and recognition of compensation expense for all stock-based awards made to employees and directors based on estimated fair values on the grant date. The Company estimates the fair value of stock-based awards on the date of grant using the Black-Scholes model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods using the straight-line method.
	The Company accounts for stock-based compensation awards to non-employees in accordance with ASC 505-50, Equity-Based Payments to Non-Employees (“ASC 505-50”). Under ASC 505-50, the Company determines the fair value of the warrants or stock-based compensation awards granted as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable.
	All issuances of stock options or other equity instruments to non-employees as consideration for goods or services received by the Company are accounted for based on the fair value of the equity instruments issued. Any stock options issued to non-employees are recorded as an expense and additional paid-in capital in stockholders’ equity over the applicable service periods.
	Advertising Costs
	Advertising costs are expensed as incurred. Advertising costs were approximately $25,955 and $53,238 for the three and six months ended June 30, 2014 and $3,453 and $5,756 for the three and six months ended June 30, 2013, and are included in sales and marketing expenses.
	Research and Development Costs
	In accordance with FASB ASC 730, research and development costs are expensed when incurred.
	Basic and Diluted Net Income per Share of Common Stock
	Basic net income per common share are based on the weighted average number of shares outstanding during the periods presented. Diluted net income per common share are computed using weighted average number of common shares plus dilutive common share equivalents outstanding during the period. Potential common shares that would have the effect of increasing diluted earnings per share are considered to be anti-dilutive, i.e. the exercise prices of the outstanding stock options were greater than the market price of the common stock. Anti-dilutive common stock equivalents, which were excluded from the calculation of number of dilutive common stock equivalents, amounted to 171,582,538 shares for the three and six months ended June 30, 2014, respectively. Because the Company reported a net loss for the three and six months ended June 30, 2013, common stock equivalents, including stock options and warrants were anti-dilutive; therefore, the amounts reported for basic and dilutive loss per share were the same.
		Three Months		Six Months
		Ended		Ended
		June 30,		June 30,
		2014		2014
	Numerator
	Net income	$	3,651,844	$	222,136
	Denominator
	Basic: Weighted-average common shares outstanding during the period		302,039,675		299,856,170
	Add: dilutive effect of warrants		450,000		450,000
	dilutive effect of conversion of preferred stock		21,111,111		21,111,111
	Diluted		323,600,786		321,417,281
	Net Income Per Share
Basic	$	0.01	$	0
Diluted	$	0.01	$	0
Segment Information
The Company is organized and operates as one operating segment wherein the Company’s patented technologies are utilized to address counterfeiting issues. In accordance with ASC 280, Segment Reporting, the chief operating decision-maker has been identified as the Chief Executive Officer, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. Since the Company operates in one segment and provides one group of similar products, all financial segment and product line information required by FASB ASC 280 can be found in the consolidated financial statements.
Recently Adopted Accounting Pronouncements
In June 2014, the FASB issued Accounting Standards Update No. 2014-10, Development State Entities (Topic 915), Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation. The amendments in this update remove the definition of a development stage entity from the Master Glossary of the Accounting Standard Codification, thereby removing the financial reporting distinction that previously required development stage entities to (1) present inception-to-date information in the statements of income, cash flow, and stockholder equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage.
The amendments also clarify that the guidance in Topic 275, Risks and Uncertainties, is applicable to entities that have not commenced planned principle operations.
The amendments related to the elimination of inception-to-date information and the other remaining disclosure requirements of Topic 915 should be applied retrospectively except for the clarification to Topic 275, which shall be applied prospectively. For public business entities, those amendments are effective for annual reporting periods beginning after December 15, 2014, and interim periods therein.
For public business entities, the amendment eliminating the exception to the sufficiency-of-equity-at-risk criterion for development stage entities in paragraph 810-10-15-16 should be applied retrospectively for annual reporting periods beginning after December 15, 2015, and interim periods therein.
Early application of each of the amendments is permitted for any annual reporting period or interim period for which the entity’s financial statements have not yet been issued (public business entities) or made available for issuance (other entities). Upon adoption entities will no longer present or disclose any information required by Topic 915.
The Company adopted the amendment retrospectively for the interim period ending June 30, 2014.
Recently Issued Accounting Pronouncements Not Yet Adopted
As of June 30, 2014, there are no recently issued accounting standards not yet adopted which would have a material effect on the Company’s financial statements.
Reclassifications
Certain amounts in the 2013 statement of operations have been classified in order for them to conform with the 2014 presentation.

MANAGEMENT_PLANS

MANAGEMENT PLANS	6 Months Ended
	Jun. 30, 2014
Management Plans [Abstract]	'
MANAGEMENT PLANS	'
	NOTE 2 – MANAGEMENT PLANS
	The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred significant losses and experienced negative cash flow from operations during the development stage. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
	The Company believes that its existing cash resources will not be sufficient to sustain operations during the next twelve months. The Company currently needs to generate revenue in order to sustain its operations. In the event that the Company cannot generate sufficient revenue to sustain its operations, the Company will need to reduce expenses or obtain financing through the sale of debt and/or equity securities. The issuance of additional equity would result in dilution to existing stockholders. If the Company is unable to obtain additional funds when they are needed or if such funds cannot be obtained on terms acceptable to the Company, the Company may be unable to execute upon the business plan or pay costs and expenses as they are incurred, which could have a material, adverse effect on the business, financial condition and results of operations.
	If sufficient revenues are not generated to sustain operations or additional funding cannot be obtained in the short term, the Company will need to reduce monthly expenditures to a level that will enable the Company to continue until such funds can be obtained.
	On June 5, 2014 the Company entered into an exclusive agreement with Merriman Capital, Inc. to raise up to but no more than $5 million in additional capital for the Company. Prior to that, on May 23, VerifyMe, Inc. waived its non-dilution rights as they relate to parameters of the raise based on the Company’s revised budget.
	Successful completion of the Company’s development program, and the attainment of profitable operations are dependent upon future events, including obtaining adequate financing to fulfill its development activities and achieving a level of sales adequate to support the Company’s cost structure. However, there can be no assurances that the Company will be able to secure additional equity investment or achieve an adequate sales level.

PATENTS_AND_TRADEMARK

PATENTS AND TRADEMARK	6 Months Ended
	Jun. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
PATENTS AND TRADEMARK	'
	NOTE 3 – PATENTS AND TRADEMARK
	The Company has five issued patents and filed for three additional provisional patents for anti-counterfeiting technology. Accordingly, costs associated with the registration of these patents and legal defense have been capitalized and are amortized on a straight-line basis over the estimated lives of the patents (17 to 20 years). During the three and six months ended June 30, 2014, the Company capitalized $0 of patent cost and during the three and six months ended June 30, 2013, the Company capitalized patent costs of $3,511 and $21,594, respectively, . Amortization expense for patents was $3,277 and $6,554 for the three and six months ended June 30, 2014 and $3,262 and $6,495 for the three and six months ended June 30, 2013, respectively. Future estimated annual amortization over the next five years is approximately $13,100 per year for the years ended December 31, 2014 through 2018.

INCOME_TAXES

INCOME TAXES	6 Months Ended
	Jun. 30, 2014
Income Tax Disclosure [Abstract]	'
INCOME TAXES	'
	NOTE 4 – INCOME TAXES
	Income tax expense was $0 for the three and six months ended June 30, 2014 and 2013.
	As of January 1, 2014, the Company had no unrecognized tax benefits, and accordingly, the Company did not recognize interest or penalties during 2014 related to unrecognized tax benefits. There has been no change in unrecognized tax benefits during the six months ended June 30, 2014, and there was no accrual for uncertain tax positions as of June 30, 2014. Tax years from 2010 through 2013 remain subject to examination by major tax jurisdictions.
	The Company has income for the three and six months ended June 30, 2014; however, due to tax adjustments, the Company has a net loss for tax purposes. There is no income tax benefit for the three and six months ended June 30, 2014 and 2013 since management has determined that the realization of the net tax deferred asset is not assured and has created a valuation allowance for the entire amount of such benefits.

SENIOR_SECURED_CONVERTIBLE_NOT

SENIOR SECURED CONVERTIBLE NOTES PAYABLE	6 Months Ended
	Jun. 30, 2014
Senior Secured Convertible Notes Payable [Abstract]	'
SENIOR SECURED CONVERTIBLE NOTES PAYABLE	'
	NOTE 5 - SENIOR SECURED CONVERTIBLE NOTES PAYABLE –RELATED PARTIES
	During the second quarter of 2014, $216,249 of principal of the Company’s outstanding senior convertible notes plus accrued interest of $208,339, were converted into 8,448,519 shares of common stock. The excess of the fair value of the Company’s common stock over the value of the notes payable and accrued interest, $82,000, was recorded as loss on extinguishment of debt in accordance with FASB ASC 470-50.
	As of June 30, 2014, the outstanding principal balance on these notes was $114,000. Accrued interest at June 30, 2014 amounted to $105,665.
	If an equity financing with total proceeds of more than $5,000,000 occurs while any of these notes are outstanding, holders of notes will have the right, at their option, to convert the outstanding principal and interest of the notes into common shares at a discount of 30% of the price per share in the qualified financing. Since the embedded conversion feature is contingent upon the occurrence of the qualified financing, the value of the contingent conversion feature, if beneficial, will be recognized if the triggering event occurs and the contingency is resolved.

NOTES_PAYABLE

NOTES PAYABLE	6 Months Ended
	Jun. 30, 2014
Debt Disclosure [Abstract]	'
NOTES PAYABLE	'
	NOTE 6 - NOTES PAYABLE
	On June 10, 2014, the Company issued a note payable for $250,000 which included warrants to purchase 1,000,000 shares of the Company’s common stock at an exercise price of $0.10 per share, expiring in five years. The warrants were valued at 39,650, using Black-Scholes option pricing model to calculate the grant-date fair value of the warrants, with the following assumptions: no dividend yield, expected volatility of 248.2%, risk free interest rate of 1.67% and expected life of 5 years. The relative fair value of the warrants was $34,222 and was recorded as a discount to the notes payable in accordance with FASB ASC 835-30-25, Recognition and is being accreted over the term of the note payable for financial statement purposes. For the three and six months ended June 30, 2014, $7,605 was accreted through interest expense. The note and accrued interest at 8% per annum are due in full on September 11, 2014. The warrants are subject to anti-dilutive adjustments and are therefore classified as a liability in accordance with FASB ASC 815. The warrant liability is re-valued at each reporting period with the change in fair value recorded through earnings. As of June 30,2014, the fair value of the warrant liability was $39,650 and the note payable balance was $223,383, net of $26,617 discount.
	The notes payable balance as of June 30, 2014 also included a Series A note payable in the amount of $50,000 with interest of 8% per annum. This note and accrued interest matured in October 2011 and is past due. Accrued interest associated with this note was $18,667 as of June 30, 2014.

WARRANT_LIABILITY

WARRANT LIABILITY	6 Months Ended
	Jun. 30, 2014
Warrants Liability [Abstract]	'
WARRANT LIABILITY	'
	NOTE 7 – WARRANT LIABILITY
	On December 31, 2012, the Company entered into an Investment Agreement, a Technology and Service Agreement, a Patent and Technology License Agreement and an Asset Purchase Agreement with VerifyMe, and on the same date entered into a Technology and Service Agreement with Zaah Technologies, Inc. (collectively with the VerifyMe agreements, the “Agreements”). Contemplated by those Agreements were warrants issuances by the Company for the purchase of the Company’s common stock.
	The warrants associated with these Agreements are subject to anti-dilution adjustments outlined in the Agreements. In accordance with FASB ASC 815, the warrants were classified as a liability in the total amount of $2.4 million at December 31, 2012. In addition, the warrants must be valued every reporting period and adjusted to market with the increase or decrease being adjusted through earnings. As of June 30, 2014 and December 31, 2013, the fair value of the warrant liability was $2,061,000 and $3,700,000.
	On January 1, 2014 the Company issued 6,349,206 warrants as consideration for technology received from VerifyMe related to the December 31, 2012 Agreement. The warrants have an exercise price of $.10 per share. The warrants are subject to anti-dilution adjustments outlined in the Agreement. In accordance with FASB ASC 815, the warrants were classified as a liability with an initial fair value of $444,000, which was immediately expensed as research and development costs. In addition, the warrants must be valued every reporting period and adjusted to market with the increase or decrease being adjusted through earnings. As of June 30, 2014, the fair value of the warrant liability was $253,000.
	The Company made the payment of warrants to VerifyMe on a good faith basis, based on the assumption that the technology conveyed to the Company would be patentable and licensable. The Company has not reached a conclusion that the technology will be patentable and licensable, and can provide no assurance to this effect.
	Should the Company ultimately conclude that the technology received from VerifyMe is patentable and licensable, the Company would be required to make, on January 1, 2015, an additional payment pursuant to Patent and Technology Agreement in the amount of $4,500,000, to be paid by issuing (i) a number of common shares equal to (x) $4,500,000 divided by (y) a price which equals a 10% discount to the market price at the time of issuance and (ii) warrants to purchase an equal number of shares of common stock exercisable at a price of $0.10 per share. Based upon the current share price of $0.07 per share, this would result in the issuance of approximately an additional 70 million shares of common stock and warrants to purchase an additional 70 million shares.

CONVERTIBLE_PREFERRED_STOCK

CONVERTIBLE PREFERRED STOCK	6 Months Ended
	Jun. 30, 2014
Features of Convertible Preferred Stock [Abstract]	'
CONVERTIBLE PREFERRED STOCK	'
	NOTE 8 – CONVERTIBLE PREFERRED STOCK
	Subscription Agreement
	The Company entered into a Subscription Agreement with VerifyMe on January 31, 2013 (the “Subscription Agreement”). Under the terms of the Subscription Agreement, VerifyMe subscribed to purchase 33,333,333 shares of the Company’s preferred stock (the “Preferred Stock”) and a warrant to purchase 33,333,333 shares of the Company’s common stock at an exercise price of $0.12 per share, for $1 million.
	At any time before January 31, 2015, VerifyMe has the right, but not the obligation, to require the Company to repurchase all, but not less than all, of the capital stock of the Company and warrants exercisable for capital stock of the Company held by VerifyMe in exchange for the price originally paid by VerifyMe therefor upon the occurrence of any of the following events:(i) the consummation of any bona fide business acquisition, (ii) the incurrence of any indebtedness by the Company in an amount in excess of $2 million, (iii) the issuance or sale of any security having a preference on liquidation senior to common stock, or (iv) the sale by the Company of capital stock or warrants exercisable for its capital stock at a price below $0.03 per share.
	In accordance with FASB ASC 480 and 815, the Preferred Stock has been classified as permanent equity and was valued at $1 million at January 31, 2013.
	The conversion feature of the Preferred Stock is an embedded derivative, which is classified as a liability in accordance with FASB ASC 815 and was valued in accordance with FASB ASC 470 as a beneficial conversion feature at a fair value of $1 million at January 31, 2013, $800,000 at December 31, 2013 and $200,000 at June 30, 2014. This was classified as an embedded derivative liability and a discount to Preferred Stock. Because the Preferred Stock can be converted at any time, the full amount of the original fair value was accreted and classified as a reduction to the discount on Preferred Stock and a deemed dividend distribution in the full amount of $1 million, in 2013.
	The warrants associated with the Preferred Stock were also classified as a liability since they are subject to anti-dilutive adjustments outlined in the warrant agreement and valued at a fair market of $2,995,791 at January 31, 2013. Because this amount was entirely in excess of the transaction price, this amount was recorded as a charge to expenses of $2,995,791 in 2013. In addition, the warrants must be valued every reporting period and adjusted to market with the increase or decrease being adjusted through earnings. As of June 30, 2014 and December 31, 2013, the fair value of the warrants was $1,288,000 and $2,300,000, respectively.
	The Preferred Stock has a preference in liquidation that the holders of the Preferred Stock are to be paid out of assets available for distribution prior to holders of common stock. The Preferred Stockholders may cast the number of votes equal to the number of whole shares of common stock into which the shares of Preferred Stock can be converted. In addition, the Preferred Stockholders are to be paid dividends, based on the number of shares of Preferred Stock as if the shares had been converted to common shares, prior to the common stockholders receiving a dividend.
	The conversion price of the shares of Preferred Stock is currently $0.03 per share. There are no arrearages on cumulative dividends.
	In August 2013, VerifyMe elected to convert in a cashless transaction an equal number of shares of Preferred Stock valued at $366,667 to 12,222,222 shares of common stock.

FAIR_VALUE_OF_FINANCIAL_INSTRU

FAIR VALUE OF FINANCIAL INSTRUMENTS	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
FAIR VALUE OF FINANCIAL INSTRUMENTS	'
	NOTE 9 – FAIR VALUE OF FINANCIAL INSTRUMENTS
	Derivative Liabilities
	For purposes of determining whether certain instruments are derivatives for accounting treatment, the Company follows the accounting standard that provides guidance for determining whether an equity-linked financial instrument, or embedded feature, is indexed to an entity’s own stock. The standard applies to any freestanding financial instruments or embedded features that have the characteristics of a derivative, and to any freestanding financial instruments that are potentially settled in an entity’s own common stock.
	Liabilities measured at fair value on a recurring basis are summarized as follows:
			Level 1			Level 2		Level 3		Total
	Derivative liability related to fair value of beneficial conversion feature		$	-		$	200,000	$	--	$	200,000
	Derivative liability related to fair value of warrants			-			-		3,641,650		3,641,650
	Total		$	-		$	200,000	$	3,641,650	$	3,841,650
	The following table details the approximate fair value measurements within the fair value hierarchy of the Company’s derivative liabilities using Level 3 inputs:
			Total
	Balance at January 1, 2014		$	6,000,000
	Additional Warrants issued January 2014			444,000
	Additional Warrants issued June 2014			34,222
	Change in fair value of derivative liabilities			(2,836,572	)
	Balance at June 30, 2014		$	3,641,650
	As of June 30, 2014, the beneficial conversion feature of the Preferred Stock is treated as an embedded derivative liability and changes in the fair value were recognized in earnings. The Preferred Stock shares are convertible into shares of the Company’s common stock, which did traded in an active securities market, therefore the embedded derivative liability was valued using the following market based inputs:
	Closing trade price of Common Stock	$	0.04
	Series A Preferred Stock Conversion Price	$	0.03
	Intrinsic value of conversion option per share	$	0.01
	The Company has no assets that are measured at fair value on a recurring basis. There were no assets or liabilities measured at fair value on a non-recurring basis during the six months ended June 30, 2014.
	As of June 30, 2014, the Company’s outstanding warrants were treated as derivative liabilities and changes in the fair value were recognized in earnings. These common stock purchase warrants did not trade in an active securities market, and as such, the Company estimated the fair value of these warrants using Black-Scholes and the following assumptions:
			30-Jun-14
	Annual Dividend Yield		0.0%
	Expected Life (Years)		3.5 – 4.51
	Risk-Free Interest Rate		1.67%
	Expected Volatility		237.8% -244.3%
	Expected volatility was based primarily on historical volatility. Historical volatility was computed using daily pricing observations for recent periods. The Company believes this method produced an estimate that was representative of the Company’s expectations of future volatility over the expected term of these warrants. The Company had no reason to believe future volatility over the expected remaining life of these warrants was likely to differ materially from historical volatility. The expected life was based on the remaining contractual term of the warrants. The risk-free rate was based on the U.S. Treasury rate that corresponded to the expected term of the warrants.

STOCKHOLDERS_EQUITY

STOCKHOLDERS' EQUITY	6 Months Ended
	Jun. 30, 2014
Stockholders' Equity Note [Abstract]	'
STOCKHOLDERS' EQUITY	'
	NOTE 10 – STOCKHOLDERS’ EQUITY
	On January 1, 2014, under the terms of the Patent and Technology License Agreement, the Company issued 6,349,206 shares of common stock to VerifyMe, in addition to the warrants described in Note 7 above. The shares were issued in payment for the technology received. Under the agreement, payment of $400,000 worth of the Company’s common stock was to be paid by the Company to VerifyMe at a 10% discount to the market at time of payment. The closing price was $0.07 per share discounted 10% to $0.063. The $400,000 payment divided by the $0.063 per share resulted in 6,349,206 shares to be issued. The entire $400,000 payment was expensed to research and development.

STOCK_OPTIONS

STOCK OPTIONS	6 Months Ended
	Jun. 30, 2014
Equity [Abstract]	'
STOCK OPTIONS	'
	NOTE 11 – STOCK OPTIONS
	During 1999, the Board of Directors (“Board”) of the Company adopted, with the approval of the stockholders, a Stock Option Plan. In 2000, the Board superseded the plan and created a new Stock Option Plan, pursuant to which it is authorized to grant options to purchase up to 1.5 million shares of common stock. On December 17, 2003, the Board, with approval of the stockholders, superseded the 2000 plan and created the 2003 Stock Option Plan (the “2003 Plan”). Under the 2003 Plan the Company is authorized to grant options to purchase up to 18,000,000 shares of common stock to the Company’s employees, officers, directors, consultants, and other agents and advisors. The Plan is intended to permit stock options granted to employees under the Plan to qualify as incentive stock options under Section 422 of the Internal Revenue Code of 1986, as amended (“Incentive Stock Options”). All options granted under the 2003 Plan, which are not intended to qualify as Incentive Stock Options, are deemed to be non-qualified options (“Non-Statutory Stock Options”).
	During 2013, our Board adopted a new omnibus incentive compensation plan (the “2013 Plan”) which will serve as the successor incentive compensation plan to the 2003 Plan, and will provide the Company with an comprehensive plan to design and structure grants of stock options, stock units, stock awards, stock appreciation rights and other stock-based awards for our employees, non-employee directors and certain consultants and advisors. Our Board of Directors believes that the availability of (i) 20,000,000 new shares of our common stock, plus (ii) the number of shares of our common stock subject to outstanding grants under the 2003 Plan as of the date of the Annual Meeting, plus (iii) the number of shares of our common stock remaining available for issuance under the 2003 Plan but not subject to previously exercised, vested or paid grants, for issuance under the 2013 Plan will be sufficient.
	As of June 30, 2014, there are 23,725,996 shares subject to outstanding options under the Plans, and 14,274,004 shares remain available for issuance.
	The 2013 Plan is administered by a committee of the Board (“Stock Option Committee”) which determines the persons to whom awards will be granted, the number of awards to be granted and the specific terms of each grant, including the vesting thereof, subject to the provisions of the plan.
	The Company issued Non-Statutory Stock Options pursuant to contractual agreements with non-employees. Options granted under the agreements are expensed when the related service or product is provided.
	Determining the appropriate fair value of stock-based awards requires the input of subjective assumptions. The Company uses the Black-Scholes option pricing model to value its stock option awards. The assumptions used in calculating the fair value represent management’s best estimates and involve inherent uncertainties and judgments.
	On January 22, 2013, the Company issued options to an employee to purchase 1,000,000 shares of the Company’s common stock at an exercise price of $0.05 per share, with a term of ten years. The options vest as follows: 250,000 immediately, 250,000 on the first anniversary of the grant date and 500,000 on the second anniversary of the grant date. The Company used the Black- Scholes option pricing model to calculate the grant-date fair value of the warrants, with the following assumptions: no dividend yield, expected volatility of 222%, risk-free interest rate of 1.9% and expected option life of ten years. The fair value of the options issued was $99,972 of which $25,000 was expensed immediately and the remainder is being expensed over the vesting terms. The total expense for the three and six months ended June 30, 2014 was $6,231 and $13,900, respectively. The total expense for the three and six months ended June 30, 2013 was $12,462 and $46,768, respectively.
	On February 25, 2013, the Company issued options to an employee to purchase 500,000 shares of the Company’s common stock at an exercise price of $0.05 per share, with a term of ten years. The options vest as follows: 200,000 on the first anniversary of the grant date, 200,000 on the second anniversary of the grant date and 100,000 on the third anniversary of the grant date. The Company used the Black-Scholes option pricing model to calculate the grant-date fair value of the warrants, with the following assumptions: no dividend yield, expected volatility of 259%, risk-free interest rate of 1.9% and expected option life of ten years. The fair value of options issued was $89,998. The total expense recognized for the three months ended March 31, 2013, was $5,000. The options were cancelled during the three months ended June 30, 2013. The total expense recognized of $5,000 was reversed upon cancellation of the options.
	On March 13, 2013, the Company issued an option to purchase 2,000,000 shares of the Company’s common stock at an exercise price of $0.05 per share, with a term of ten years, to a member of the Board. The options vested 50% immediately and 50% on March 13, 2014. The Company used the Black-Scholes option pricing model to calculate the grant-date fair value of the warrants, with the following assumptions: no dividend yield, expected volatility of 235%, risk-free interest rate of 2.0% and expected option life of ten years. The fair value of the option issued was $439,963 of which $219,982 was expensed immediately and the remainder will be expensed over one year. There was no expense recognized for the three months ended June 30, 2014. The total expense recognized for the six months ended June 30, 2014 was $43,394. The total expense for the three and six months ended June 30, 2013 was $54,845 and $285,675, respectively.
	On May 4, 2013, the Company issued an option to purchase 2,000,000 shares of the Company’s common stock at an exercise price of $0.05 per share, with a term of ten years, to a member of the Board. The options vest 50% immediately and 50% on May 4, 2014. The Company used the Black-Scholes option pricing model to calculate the grant-date fair value of the warrants, with the following assumptions: no dividend yield, expected volatility of 235%, risk-free interest rate of 1.78% and expected option life of ten years. The fair value of the option issued was $460,000 of which $230,000 was expensed immediately and the remainder will be expensed over one year. The total expense for the three and six months ended June 30, 2014 was $21,425 and $78,137.
	On September 30, 2013, the Company issued an option to purchase 1,000,000 shares of the Company’s common stock at an exercise price of $0.15 per share, with a term of ten years, to the Company’s Chief Operating Officer. The options vest 50% after the first year and 50% at the end of 24 months after the grant date. The Company used the Black-Scholes option pricing model to calculate the grant-date fair value of the warrants, with the following assumptions: no dividend yield, expected volatility of ranging from 268.4% to 272.8%, risk-free interest rate of 1.39% and expected option life ranging from 10 years. The fair value of the option issued was $99,840. The total expense for the three and six months ended June 30, 2014 was $18,698 and $37,190, respectively.
	On December 2, 2013, the Company issued an option to purchase 1 million shares of the Company’s common stock at an exercise after the grant date price of $0.15 per share, with a term of ten years, to the Company’s Chief Financial Officer. The options vest 50% after the first year and 50% at the end of 24 months. The Company used the Black-Scholes option pricing model to calculate the grant-date fair value of the warrants, with the following assumptions: no dividend yield, expected volatility of ranging from 266.1%, risk-free interest rate of 2.64% and expected option life of 10 years. The fair value of the option issued was $79,994, which will be expensed over the vesting term. The total expense for the three and six months ended June 30, 2014 was $14,958 and $29,752, respectively.
	On March 28, 2014, the Company issued options to purchase an aggregate of 6,000,000 shares of the Company’s common stock at an exercise price of $0.05 per share, with a term of ten years, to one member of the Board. The fair value of options issued was $599,893 of which all was expensed immediately.
	All of the options issued on March 28, 2014 were valued using the Black-Scholes option pricing model to calculate the grant-date fair value of the options, with the following assumptions: no dividend yield, expected volatility of 229%, risk-free interest rate of 2.73% and expected option life of ten years.
	On February 7, 2014, options to purchase 6,000,000 shares of the Company’s common stock were exercised on a cashless basis. Based on a stock price of $0.07 per share and an exercise price of $0.05 per share, the option exercise resulted in the issuance of 1,714,285 shares of common stock to the holder.
	On February 25, 2014, options to purchase 6,000,000 shares of the Company’s Common Stock were exercised by the Company’s Chief Executive Officer on a cashless basis. Based on a stock price of $0.06 per share and an exercise price of $0.05 per share, the option exercise resulted in the issuance of 1,000,000 shares of common stock to the holder.
	The following tables summarize non-employee stock option/warrant activity of the Company since December 31, 2013:
		Option/Warrant			Exercise		Weighted Average
		Shares			Price		Exercise
							Price
	Outstanding, December 31, 2013		111,516,665		$	0.01 to 0.20		0.09
	Granted		1,000,000			0.1		0.001
	Exercised		6,349,209			0.1		0.01
	Expired/Returned		(700,000	)		.07 - .20		-
	Outstanding, June 30, 2014		118,165,874			$0.01 to $.20	$	0.1
	Exercisable, June 30, 2014		118,165,874			$0.01 to $.20	$	0.1
	Weighted Average Remaining Life,		6.3
	Exercisable, June 30, 2014 (years)
	A summary of incentive stock option transactions for employees since December 31, 2013 is as follows:
		Option/Warrant			Exercise		Weighted Average
		Shares			Price		Exercise
							Price
	Outstanding, December 31, 2013		59,866,667		$	.05 to .15		0.05
	Granted		6,000,000			0.05		0.01
	Exercised		(12,000,000	)		0.05		0.01
	Expired/Returned		-			-		-
	Outstanding, June 30, 2014		53,866,667			$0.05 to $0.15	$	0.05
	Exercisable, June 30, 2014		45,366,667			$0.05 to $0.15	$	0.06
	Weighted Average Remaining Life,		9.1
	Exercisable, June 30, 2014 (years)

OPERATING_LEASES

OPERATING LEASES	6 Months Ended
	Jun. 30, 2014
Leases, Operating [Abstract]	'
OPERATING LEASES	'
	NOTE 12 - OPERATING LEASES
	For the three and six months ended June 30, 2014, total rent expense under leases amounted to $17,766 and $35,493. For the three and six months ended June 30, 2013, total rent expense under leases amounted to $12,344 and $18,344. At June 30, 2014, the Company was obligated under various non-cancelable operating lease arrangements for property as follows:
		2014	$	36,468
		2015		74,637
		2016		31,605
			$	142,710

RELATED_PARTY_TRANSACTIONS

RELATED PARTY TRANSACTIONS	6 Months Ended
	Jun. 30, 2014
Related Party Transactions [Abstract]	'
RELATED PARTY TRANSACTIONS	'
	NOTE 13 – RELATED PARTY TRANSACTIONS
	At June 30, 2014, three stockholders of the Company held $164,000 in principal of the Company’s convertible notes payable and were owed accrued interest of $124,332 related to such notes.

CONTINGENCIES

CONTINGENCIES	6 Months Ended
	Jun. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
CONTINGENCIES	'
	NOTE 14 – CONTINGENCIES
	In October 2010, the Company filed suit in the Western District of Pennsylvania against WS Packaging Group, Inc. (“WS”) alleging that WS infringed on one of the Company’s patents in the manufacture of MONOPOLY game pieces on behalf of McDonald’s Corp. On June 4, 2012, both WS and the Company filed a stipulation to dismiss the action without prejudice and enter into settlement negotiations. Settlement negotiations are ongoing.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	6 Months Ended
	Jun. 30, 2014
Subsequent Events [Abstract]	'
SUBSEQUENT EVENTS	'
	NOTE 15 – SUBSEQUENT EVENTS
	On July 31, 2014, the Company announced it has signed a 10-year, $7 million contract with a Mexican gaming company to license its VerifyMe™ Identity Services. The technology will be used to authenticate players in online casinos run by the gaming company and to meet the requirements of recently passed anti-money laundering legislation in Mexico.
	On August 11, 2014 the Company was notified by the United States Patent and Trademark Office that a third independent patent for it's state-of-the-art SecureLight+ technology had been allowed.

SUMMARY_OF_SIGNIFICANT_ACCOUNT1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Principle of Consolidation	'
	Principle of Consolidation
	The accompanying condensed consolidated financial statements include the accounts of LaserLock Technologies Inc. and its wholly-owned subsidiary, LL Security Products, Inc. All inter-company transactions have been eliminated in consolidation.
Use of Estimates	'
	Use of Estimates
	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.
Comprehensive Income	'
	Comprehensive Income
	The Company follows Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 220 in reporting comprehensive income. Comprehensive income is a more inclusive financial reporting methodology that involves disclosure of certain financial information that historically has not been recognized in the calculation of net income. Since the Company has no items of other comprehensive income (loss), comprehensive income (loss) is equal to net income (loss).
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	The Company’s financial instruments consist of cash, accounts receivable, accounts payable and accrued expenses, embedded derivative, warrant liability and notes payable. The carrying value of cash, accounts receivable, accounts payable and accrued expenses approximate their fair value because of their short maturities. The Company believes the carrying amount of its notes payable and convertible debt approximates its fair value based on rates and other terms currently available to the Company for similar debt instruments.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	For purposes of reporting cash flows, the Company considers all cash accounts, which are not subject to withdrawal restrictions or penalties, and certificates of deposit and commercial paper with original maturities of 90 days or less to be cash or cash equivalents.
Concentration of Credit Risk Involving Cash and Cash Equivalents	'
	Concentration of Credit Risk Involving Cash and Cash Equivalents
	The Company’s cash and cash equivalents are held at two financial institutions. At times, the Company’s deposits may exceed Federal Deposit Insurance Corporation (FDIC) coverage limits. The Company has not experienced any losses from maintaining cash accounts in excess of federally insured limits.
Inventory	'
	Inventory
	Inventory principally consists of penlights and pigments and is stated at the lower of cost (determined by the first-in, first-out method) or market.
Property and Equipment	'
	Property and Equipment
	Property and equipment is stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, principally five to seven years. Maintenance and repairs of property are charged to operations, and major improvements are capitalized. Upon retirement, sale, or other disposition of property and equipment, the costs and accumulated depreciation are eliminated from the accounts, and any resulting gain or loss is included in operations. Depreciation of property and equipment was $17,313 and $34,627 for the three and six months ended June 30, 2014 and $33,900 and $34,212 for the three and six months ended June 30, 2013.
Patents and Trademark	'
	Patents and Trademark
	The Company has five issued patents, filed for three provisional patents for anti-counterfeiting technology and purchased a trademark. Costs associated with the registration and legal defense of the patents have been capitalized and are amortized on a straight-line basis over the estimated lives of the patents that were determined to be17 to 20 years.
Long-Lived Assets	'
	Long-Lived Assets
	The Company evaluates the recoverability of its long-lived assets in accordance with ASC 360 “Property, Plant, and Equipment.” The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets is measured by a comparison of the carrying amount of an asset to future cash flows expected to be generated by the asset, undiscounted and without interest or independent appraisals. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the assets.
Deferred Financing Costs	'
	Deferred Financing Costs
	Costs incurred in securing long-term debt are deferred and amortized, as a charge to interest expense, over the term of the related debt. In the case of long-term debt modifications, the Company follows the guidance provided by ASC 470-50 “Debt – Modification and Extinguishments.”
Convertible Notes Payable	'
	Convertible Notes Payable
	Convertible notes payable, for which the embedded conversion feature does not qualify for derivative treatment, are evaluated to determine if the effective or actual rate of conversion per the terms of the convertible note agreement is below market value. In these instances, the Company accounts for the value of the beneficial conversion feature (BCF) as a debt discount, which is then accreted to interest expense over the life of the related debt using the straight-line method, which approximates the effective interest method.
Derivative Instruments	'
	Derivative Instruments
	The Company evaluates its convertible debt, warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with Topic 480 of the FASB ASC and Topic 815 of the FASB Accounting Standards Codification. The result of this accounting treatment is that the fair value of the embedded derivative if required to be bifurcated is marked-to-market at each balance sheet date and recorded as a liability. The change in fair value is recorded in the Statement of Operations as a component of other income or expense. Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity.
	In circumstances where the embedded conversion option in a convertible instrument is required to be bifurcated and there are also other embedded derivative instruments in the convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument.
	The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Equity instruments that are initially classified as equity that become subject to reclassification are reclassified to liability at the fair value of the instrument on the reclassification date. Derivative instrument liabilities will be classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is expected within 12 months of the balance sheet date.
Revenue Recognition	'
	Revenue Recognition
	In accordance with SEC Staff Accounting Bulletin No. 104, Revenue Recognition (Codified in FASB ASC 605), the Company recognizes revenue when (i) persuasive evidence of a customer or distributor arrangement exists, (ii) a retailer, distributor or wholesaler receives the goods and acceptance occurs, (iii) the price is fixed or determinable, and (iv) collectability of the revenue is reasonably assured. Subject to these criteria, the Company recognizes revenue from product sales, consisting mainly of pigments and penlights, upon shipment to the customer. Royalty revenue is recognized upon receipt of notification from a customer that the Company’s product has been used in the customer’s production process.
Income Taxes	'
	Income Taxes
	The Company follows FASB ASC 740 when accounting for income taxes, which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed annually for temporary differences between the financial statements and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Income tax expense is the tax payable or refundable for the period plus or minus the change during the period in deferred tax assets and liabilities.
Stock-based Payments	'
	Stock-based Payments
	The Company accounts for stock-based compensation under the provisions of ASC 718, Compensation—Stock Compensation, which requires the measurement and recognition of compensation expense for all stock-based awards made to employees and directors based on estimated fair values on the grant date. The Company estimates the fair value of stock-based awards on the date of grant using the Black-Scholes model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods using the straight-line method.
	The Company accounts for stock-based compensation awards to non-employees in accordance with ASC 505-50, Equity-Based Payments to Non-Employees (“ASC 505-50”). Under ASC 505-50, the Company determines the fair value of the warrants or stock-based compensation awards granted as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable.
	All issuances of stock options or other equity instruments to non-employees as consideration for goods or services received by the Company are accounted for based on the fair value of the equity instruments issued. Any stock options issued to non-employees are recorded as an expense and additional paid-in capital in stockholders’ equity over the applicable service periods.
Advertising Costs	'
	Advertising Costs
	Advertising costs are expensed as incurred. Advertising costs were approximately $25,955 and $53,238 for the three and six months ended June 30, 2014 and $3,453 and $5,756 for the three and six months ended June 30, 2013, and are included in sales and marketing expenses.
Research and Development Costs	'
	Research and Development Costs
	In accordance with FASB ASC 730, research and development costs are expensed when incurred.
Basic and Diluted Net Income per Share of Common Stock	'
	Basic and Diluted Net Income per Share of Common Stock
	Basic net income per common share are based on the weighted average number of shares outstanding during the periods presented. Diluted net income per common share are computed using weighted average number of common shares plus dilutive common share equivalents outstanding during the period. Potential common shares that would have the effect of increasing diluted earnings per share are considered to be anti-dilutive, i.e. the exercise prices of the outstanding stock options were greater than the market price of the common stock. Anti-dilutive common stock equivalents, which were excluded from the calculation of number of dilutive common stock equivalents, amounted to 171,582,538 shares for the three and six months ended June 30, 2014, respectively. Because the Company reported a net loss for the three and six months ended June 30, 2013, common stock equivalents, including stock options and warrants were anti-dilutive; therefore, the amounts reported for basic and dilutive loss per share were the same.
		Three Months		Six Months
		Ended		Ended
		June 30,		June 30,
		2014		2014
	Numerator
	Net income	$	3,651,844	$	222,136
	Denominator
	Basic: Weighted-average common shares outstanding during the period		302,039,675		299,856,170
	Add: dilutive effect of warrants		450,000		450,000
	dilutive effect of conversion of preferred stock		21,111,111		21,111,111
	Diluted		323,600,786		321,417,281
	Net Income Per Share
	Basic	$	0.01	$	0
	Diluted	$	0.01	$	0
Segment Information	'
	Segment Information
	The Company is organized and operates as one operating segment wherein the Company’s patented technologies are utilized to address counterfeiting issues. In accordance with ASC 280, Segment Reporting, the chief operating decision-maker has been identified as the Chief Executive Officer, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. Since the Company operates in one segment and provides one group of similar products, all financial segment and product line information required by FASB ASC 280 can be found in the consolidated financial statements.
Recently Adopted Accounting Pronouncements	'
	Recently Adopted Accounting Pronouncements
	In June 2014, the FASB issued Accounting Standards Update No. 2014-10, Development State Entities (Topic 915), Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation. The amendments in this update remove the definition of a development stage entity from the Master Glossary of the Accounting Standard Codification, thereby removing the financial reporting distinction that previously required development stage entities to (1) present inception-to-date information in the statements of income, cash flow, and stockholder equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage.
	The amendments also clarify that the guidance in Topic 275, Risks and Uncertainties, is applicable to entities that have not commenced planned principle operations.
	The amendments related to the elimination of inception-to-date information and the other remaining disclosure requirements of Topic 915 should be applied retrospectively except for the clarification to Topic 275, which shall be applied prospectively. For public business entities, those amendments are effective for annual reporting periods beginning after December 15, 2014, and interim periods therein.
	For public business entities, the amendment eliminating the exception to the sufficiency-of-equity-at-risk criterion for development stage entities in paragraph 810-10-15-16 should be applied retrospectively for annual reporting periods beginning after December 15, 2015, and interim periods therein.
	Early application of each of the amendments is permitted for any annual reporting period or interim period for which the entity’s financial statements have not yet been issued (public business entities) or made available for issuance (other entities). Upon adoption entities will no longer present or disclose any information required by Topic 915.
	The Company adopted the amendment retrospectively for the interim period ending June 30, 2014.
Recently Issued Accounting Pronouncements Not Yet Adopted	'
	Recently Issued Accounting Pronouncements Not Yet Adopted
	As of June 30, 2014, there are no recently issued accounting standards not yet adopted which would have a material effect on the Company’s financial statements.
Reclassification	'
	Reclassifications
	Certain amounts in the 2013 statement of operations have been classified in order for them to conform with the 2014 presentation.

SUMMARY_OF_SIGNIFICANT_ACCOUNT2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Schedule of basic and diluted net income per share of common stock	'
		Three Months		Six Months
		Ended		Ended
		June 30,		June 30,
		2014		2014
	Numerator
	Net income	$	3,651,844	$	222,136
	Denominator
	Basic: Weighted-average common shares outstanding during the period		302,039,675		299,856,170
	Add: dilutive effect of warrants		450,000		450,000
	dilutive effect of conversion of preferred stock		21,111,111		21,111,111
	Diluted		323,600,786		321,417,281
	Net Income Per Share
	Basic	$	0.01	$	0
	Diluted	$	0.01	$	0

FAIR_VALUE_OF_FINANCIAL_INSTRU1

FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Schedule of liabilities measured at fair value on a recurring basis	'
			Level 1			Level 2		Level 3		Total
	Derivative liability related to fair value of beneficial conversion feature		$	-		$	200,000	$	--	$	200,000
	Derivative liability related to fair value of warrants			-			-		3,641,650		3,641,650
	Total		$	-		$	200,000	$	3,641,650	$	3,841,650
Schedule of fair value measurements within the fair value hierarchy of derivative liabilities using Level 3 inputs	'
			Total
	Balance at January 1, 2014		$	6,000,000
	Additional Warrants issued January 2014			444,000
	Additional Warrants issued June 2014			34,222
	Change in fair value of derivative liabilities			(2,836,572	)
	Balance at June 30, 2014		$	3,641,650
Schedule of embedded derivative liability valuation assumptions	'
	Closing trade price of Common Stock	$	0.04
	Series A Preferred Stock Conversion Price	$	0.03
	Intrinsic value of conversion option per share	$	0.01
Schedule of common stock purchase warrants valuation assumptions	'
			30-Jun-14
	Annual Dividend Yield		0.0%
	Expected Life (Years)		3.5 – 4.51
	Risk-Free Interest Rate		1.67%
	Expected Volatility		237.8% -244.3%

STOCK_OPTIONS_Tables

STOCK OPTIONS (Tables)	6 Months Ended
	Jun. 30, 2014
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]	'
Schedule of non-employee stock option/warrant activity	'
		Option/Warrant			Exercise		Weighted Average
		Shares			Price		Exercise
							Price
	Outstanding, December 31, 2013		111,516,665		$	0.01 to 0.20		0.09
	Granted		1,000,000			0.1		0.001
	Exercised		6,349,209			0.1		0.01
	Expired/Returned		(700,000	)		.07 - .20		-
	Outstanding, June 30, 2014		118,165,874			$0.01 to $.20	$	0.1
	Exercisable, June 30, 2014		118,165,874			$0.01 to $.20	$	0.1
	Weighted Average Remaining Life,		6.3
	Exercisable, June 30, 2014 (years)
Schedule of incentive stock option transactions for employees	'
		Option/Warrant			Exercise		Weighted Average
		Shares			Price		Exercise
							Price
	Outstanding, December 31, 2013		59,866,667		$	.05 to .15		0.05
	Granted		6,000,000			0.05		0.01
	Exercised		(12,000,000	)		0.05		0.01
	Expired/Returned		-			-		-
	Outstanding, June 30, 2014		53,866,667			$0.05 to $0.15	$	0.05
	Exercisable, June 30, 2014		45,366,667			$0.05 to $0.15	$	0.06
	Weighted Average Remaining Life,		9.1
	Exercisable, June 30, 2014 (years)

OPERATING_LEASES_Tables

OPERATING LEASES (Tables)	6 Months Ended
	Jun. 30, 2014
Leases, Operating [Abstract]	'
Schedule of non-cancelable operating lease arrangements for property	'
		2014	$	36,468
		2015		74,637
		2016		31,605
			$	142,710

SUMMARY_OF_SIGNIFICANT_ACCOUNT3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Numerator	'	'	'	'
Net income	$3,651,844	($10,759,550)	$222,136	($26,666,194)
Dinominator	'	'	'	'
Basic: Weighted-average common shares outstanding during the period	302,039,675	240,935,887	299,856,170	233,374,035
Add: dilutive effect of warrants	450,000	'	450,000	'
dilutive effect of conversion of preferred stock	21,111,111	'	21,111,111	'
Diluted	323,600,786	240,935,887	321,417,281	233,374,035
Net Income Per Share	'	'	'	'
Basic (in dollars per share)	($0.01)	$0.04	$0	$0.11
Diluted (in dollars per share)	($0.01)	$0.04	$0	$0.11

SUMMARY_OF_SIGNIFICANT_ACCOUNT4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Detail Textuals) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
			Segment
			Institution
Schedule Of Significant Accounting Policies [Line Items]	'	'	'	'
Number of financial institutions at which company's cash and cash equivalents are held	'	'	2	'
Depreciation method of Property and equipment	'	'	'straight-line method	'
Estimated useful lives Property and equipment	'	'	'five to seven years	'
Depreciation on Property and equipment	$17,313	$33,900	$34,627	$34,212
Anti-dilutive common stock equivalents, excluded from the calculation of earnings per share	171,582,538	'	171,582,538	'
Number of operating segment	'	'	1	'
Sales and marketing expenses	'	'	'	'
Schedule Of Significant Accounting Policies [Line Items]	'	'	'	'
Advertising costs	$25,955	$3,453	$53,238	$5,756
Patents and Trademark	'	'	'	'
Schedule Of Significant Accounting Policies [Line Items]	'	'	'	'
Number of patents issued	'	'	5	'
Number of provisional patents filed	'	'	3	'
Amortization method of patents	'	'	'straight-line basis	'
Patents and Trademark | Minimum	'	'	'	'
Schedule Of Significant Accounting Policies [Line Items]	'	'	'	'
Estimated lives of patents	'	'	'17 years	'
Patents and Trademark | Maximum	'	'	'	'
Schedule Of Significant Accounting Policies [Line Items]	'	'	'	'
Estimated lives of patents	'	'	'20 years	'

MANAGEMENT_PLANS_Detail_Textua

MANAGEMENT PLANS (Detail Textuals) (Exclusive Agreement, USD $)	Jun. 05, 2014
In Millions, unless otherwise specified
Exclusive Agreement	'
Management Plans [Line Items]	'
Threshold limit for additional borrowing	$5

PATENTS_AND_TRADEMARK_Detail_T

PATENTS AND TRADEMARK (Detail Textuals) (Patents and Trademark, USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
			Patent
Finite-Lived Intangible Assets [Line Items]	'	'	'	'
Number of patents issued	'	'	5	'
Number of provisional patents filed	'	'	3	'
Amortization method of patents	'	'	'straight-line basis	'
Capitalized patent costs	$0	$3,511	$0	$21,594
Amortization expense	3,277	3,262	6,554	6,495
Future estimated annual amortization in December 31, 2014	13,100	'	13,100	'
Future estimated annual amortization in December 31, 2015	13,100	'	13,100	'
Future estimated annual amortization in December 31, 2016	13,100	'	13,100	'
Future estimated annual amortization in December 31, 2017	13,100	'	13,100	'
Future estimated annual amortization in December 31, 2018	$13,100	'	$13,100	'
Minimum	'	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'	'
Estimated lives of patents	'	'	'17 years	'
Maximum	'	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'	'
Estimated lives of patents	'	'	'20 years	'

INCOME_TAXES_Detail_Textuals

INCOME TAXES (Detail Textuals) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Income Tax Disclosure [Abstract]	'	'	'	'
Income Tax Expense (Benefit)	'	'	'	'

SENIOR_SECURED_CONVERTIBLE_NOT1

SENIOR SECURED CONVERTIBLE NOTES PAYABLE (Detail Textuals) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Debt Instrument [Line Items]	'	'	'	'
Loss on extinguishment of debt	($82,000)	($1,221,875)	($82,000)	($1,221,875)
Senior Secured Convertible Notes Payable	'	'	'	'
Debt Instrument [Line Items]	'	'	'	'
Amount of notes converted into common stock shares	216,249	'	'	'
Accrued interest of notes converted into common stock shares	208,339	'	'	'
Common stock shares issued on conversion of debt (in shares)	8,448,519	'	'	'
Loss on extinguishment of debt	82,000	'	'	'
Outstanding principal balance on notes	114,000	'	114,000	'
Accrued interest	$105,665	'	$105,665	'

SENIOR_SECURED_CONVERTIBLE_NOT2

SENIOR SECURED CONVERTIBLE NOTES PAYABLE (Detail Textuals 1) (Senior Secured Convertible Notes Payable)	6 Months Ended
	Jun. 30, 2014
Senior Secured Convertible Notes Payable	'
Debt Instrument [Line Items]	'
Debt instrument conditional covenants amount	'if an equity financing with total proceeds of more than $5,000,000 occurs while any notes are outstanding, holders of notes will have the right, at their option, to convert the outstanding principal and interest of the notes into shares at a discount of 30% of the price per share in the qualified financing.
Percentage of discount on price per share	30.00%

NOTES_PAYABLE_Detail_Textuals

NOTES PAYABLE (Detail Textuals) (USD $)	3 Months Ended		6 Months Ended			3 Months Ended	6 Months Ended	0 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013	Jun. 30, 2014	Jun. 30, 2014	Jun. 10, 2014	Jun. 30, 2014
						Notes Payable	Notes Payable	Notes Payable	Series A Notes Payable
								Warrant
Debt Instrument [Line Items]	'	'	'	'	'	'	'	'	'
Proceeds from issuance of notes payable	'	'	$250,000	'	'	'	'	$250,000	'
Number of common stock called by warrants (in shares)	'	'	'	'	'	'	'	1,000,000	'
Exercise price (in dollars per share)	'	'	'	'	'	'	'	$0.10	'
Fair value of warrant liability	39,650	'	39,650	'	'	'	'	39,650	'
Expected volatility	'	'	'	'	'	'	'	248.20%	'
Risk-free interest rate	'	'	'	'	'	'	'	1.67%	'
Expected warrant term	'	'	'	'	'	'	'	'5 years	'
Interest expense	13,121	32,978	24,028	74,219	'	7,605	7,605	'	'
Notes payable	'	'	'	'	'	'	'	'	50,000
Interest rate, notes payable	'	'	'	'	'	8.00%	8.00%	'	8.00%
Accrued interest	'	'	'	'	'	'	'	'	18,667
Discount, notes payable (in dollars)	26,617	'	26,617	'	'	'	'	34,222	'
Note payable balance	$273,383	'	$273,383	'	$50,000	'	'	'	'

WARRANT_LIABILITY_Detail_Textu

WARRANT LIABILITY (Detail Textuals) (USD $)	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2014	Jan. 01, 2014	Jun. 30, 2014	Dec. 31, 2013	Dec. 31, 2012	Jan. 01, 2014	Dec. 31, 2012	Jun. 30, 2014
			Verify Me	Verify Me	Agreements	Agreements	Agreements	Agreements	Patent And Technology Agreement	Patent And Technology Agreement
			Warrants issued on January 1, 2014	Warrants issued on January 1, 2014	Zaah Technologies	Zaah Technologies	Zaah Technologies	Verify Me		Verify Me
								Research and Development Expense
Major Agreements [Line Items]	'	'	'	'	'	'	'	'	'	'
Warrant liability	$3,641,650	$6,000,000	'	'	'	'	$2,400,000	'	'	'
Fair value of warrant liability	39,650	'	253,000	'	2,061,000	3,700,000	'	'	'	'
Number of warrants issued	'	'	'	6,349,206	'	'	'	'	'	'
Exercise price (in dollars per share)	'	'	'	$0.10	'	'	'	'	$0.10	'
Initial fair value of warrant expensed as research and development cost	'	'	'	'	'	'	'	444,000	'	'
Additional payment for patent and technology	'	'	'	'	'	'	'	'	$4,500,000	'
Discount to market price at time of issuance	'	'	'	'	'	'	'	'	10.00%	'
Current share price (in dollars per share)	$0.04	'	'	'	'	'	'	'	$0.07	'
Additional shares issued for patent and technology agreement (in shares)	'	'	'	'	'	'	'	'	70,000,000	6,349,206
Number of common stock shares purchased under warrants (in shares)	'	'	'	'	'	'	'	'	70,000,000	'

CONVERTIBLE_PREFERRED_STOCK_De

CONVERTIBLE PREFERRED STOCK (Detail textuals) (USD $)	6 Months Ended	12 Months Ended	1 Months Ended		6 Months Ended	12 Months Ended		1 Months Ended
	Jun. 30, 2014	Dec. 31, 2013	Jan. 31, 2013	Jan. 31, 2013	Jun. 30, 2014	Dec. 31, 2013	Dec. 31, 2013	Aug. 31, 2013	Jan. 31, 2013	Aug. 31, 2013	Jan. 31, 2013
			Subscription Agreement	Subscription Agreement	Subscription Agreement	Subscription Agreement	Subscription Agreement	Subscription Agreement	Subscription Agreement	Subscription Agreement	Subscription Agreement
				Verify Me	Verify Me	Verify Me	Preferred Class	Convertible Preferred Stock	Convertible Preferred Stock	Common Stock	Common Stock
								Verify Me	Verify Me	Verify Me	Verify Me
Class of Stock [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Number of preferred stock purchased	'	'	'	'	'	'	'	'	33,333,333	'	'
Number of common stock called by warrants (in shares)	'	'	'	'	'	'	'	'	'	'	33,333,333
Value of shares issued	'	'	'	'	'	'	'	'	'	'	$1,000,000
Exercise price of warrants	'	'	'	'	'	'	'	'	$0.12	'	$0.12
Convertible preferred stock description	'	'	'(i) the consummation of any bona fide business acquisition, (ii) the incurring of any indebtedness by the Company in an amount in excess of $2 million, (iii) the issuance or sale of any security having a preference on liquidation senior to common stock, or (iv) the sale by the Company of capital stock or warrants exercisable for its capital stock at a price below $0.03 per share.	'	'	'	'	'	'	'	'
Excess amount for incurring indebtedness	'	'	2,000,000	'	'	'	'	'	'	'	'
Exercise price of capital stock or warrant	'	'	$0.03	'	'	'	'	'	'	'	'
Preferred stock value	633,333	633,333	1,000,000	'	'	'	'	'	'	'	'
Beneficial conversion feature at fair market value	'	'	'	1,000,000	200,000	800,000	'	'	'	'	'
Fair value of warrants	1,288,000	2,300,000	2,995,791	'	'	'	'	'	'	'	'
Fair value of warrants recorded as charge to expenses	'	'	2,995,791	'	'	'	'	'	'	'	'
Initial conversion price per share (in dollars per share)	'	'	'	'	'	'	$0.03	'	'	'	'
Preferred stock value in noncash transaction	'	'	'	'	'	'	'	$366,667	'	'	'
Shares of common stock shares issued on conversion	'	'	'	'	'	'	'	'	'	12,222,222	'

FAIR_VALUE_OF_FINANCIAL_INSTRU2

FAIR VALUE OF FINANCIAL INSTRUMENTS - Liabilities measured at fair value on recurring basis (Details) (Fair value on a recurring basis, USD $)	Jun. 30, 2014
Level 1	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Derivative liability related to fair value of beneficial conversion feature	'
Derivative liability related to fair value of warrants	'
Total	'
Level 2	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Derivative liability related to fair value of beneficial conversion feature	200,000
Derivative liability related to fair value of warrants	'
Total	200,000
Level 3	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Derivative liability related to fair value of beneficial conversion feature	'
Derivative liability related to fair value of warrants	3,641,650
Total	3,641,650
Total	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Derivative liability related to fair value of beneficial conversion feature	200,000
Derivative liability related to fair value of warrants	3,641,650
Total	$3,841,650

FAIR_VALUE_OF_FINANCIAL_INSTRU3

FAIR VALUE OF FINANCIAL INSTRUMENTS - Fair value measurements within fair value hierarchy of derivative liabilities using Level 3 inputs (Details 1) (USD $)	6 Months Ended
	Jun. 30, 2014
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]	'
Balance at January 1, 2014	$6,000,000
Additional Warrants issued January 2014	444,000
Additional Warrants issued June 2014	34,222
Change in fair value of derivative liabilities	-2,836,572
Balance at June 30, 2014	$3,641,650

FAIR_VALUE_OF_FINANCIAL_INSTRU4

FAIR VALUE OF FINANCIAL INSTRUMENTS - Estimated fair value of embedded derivative liability using Black-Scholes (Details 2) (USD $)	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Closing trade price of Common Stock	$0.04
Series A Preferred Stock Conversion Price	$0.03
Intrinsic value of conversion option per share	$0.01

FAIR_VALUE_OF_FINANCIAL_INSTRU5

FAIR VALUE OF FINANCIAL INSTRUMENTS - Estimated fair value of warrants using Black-Scholes (Details 3) (Warrants treated as Derivative Liabilities)	6 Months Ended
	Jun. 30, 2014
Fair Value Inputs Quantitative Information [Line Items]	'
Annual Dividend Yield	0.00%
Risk-Free Interest Rate	1.67%
Minimum	'
Fair Value Inputs Quantitative Information [Line Items]	'
Expected Life (Years)	'3 years 6 months
Expected Volatility	237.80%
Maximum	'
Fair Value Inputs Quantitative Information [Line Items]	'
Expected Life (Years)	'4 years 6 months 4 days
Expected Volatility	244.30%

STOCKHOLDERS_EQUITY_Detail_Tex

STOCKHOLDERS' EQUITY (Detail Textuals) (USD $)	3 Months Ended				6 Months Ended				12 Months Ended	6 Months Ended
	Jun. 30, 2014		Jun. 30, 2013		Jun. 30, 2014		Jun. 30, 2013		Dec. 31, 2012	Jun. 30, 2014
									Patent And Technology Agreement	Patent And Technology Agreement
										Verify Me
Stockholders Equity Note [Line Items]	'		'		'		'		'	'
Issuance of shares for services (in shares)	'		'		'		'		70,000,000	6,349,206
Worth of common stock to be paid	'		'		$400,000		'		'	$400,000
Percentage of discount	'		'		'		'		'	10.00%
Closing price of share	'		'		'		'		'	$0.07
Closing price of share after discount	'		'		'		'		'	$0.06
Research and development (b)	$30,120	[1]	$162,819	[1]	$875,849	[1]	$137,424	[1]	'	$400,000
[1]	Includes share based compensation of $400,000 for the six months ended June 30, 2014 related to the Patent and Technology License Agreement.

STOCK_OPTIONS_NonEmployee_Stoc

STOCK OPTIONS - Non-Employee Stock Option/Warrant Activity (Details) (Stock Options and Warrants, USD $)	6 Months Ended
	Jun. 30, 2014
Option/Warrant Shares	'
Outstanding, December 31, 2013	111,516,665
Granted	1,000,000
Exercised	6,349,209
Expired/Returned	-700,000
Outstanding, June 30, 2014	118,165,874
Exercisable, June 30, 2014	118,165,874
Weighted Average Remaining Life, Exercisable, June 30, 2014 (years)	'6 years 3 months 18 days
Exercise Price	'
Granted	$0.10
Exercised	$0.10
Weighted Average Exercise Price	'
Outstanding, December 31, 2013	$0.09
Granted	$0.00
Exercised	$0.01
Expired/Returned	'
Outstanding, June 30, 2014	$0.10
Exercisable, June 30, 2014	$0.10
Minimum	'
Exercise Price	'
Outstanding, December 31, 2013	$0.01
Expired/Returned	$0.07
Outstanding, June 30, 2014	$0.01
Exercisable, June 30, 2014	$0.01
Maximum	'
Exercise Price	'
Outstanding, December 31, 2013	$0.20
Expired/Returned	$0.20
Outstanding, June 30, 2014	$0.20
Exercisable, June 30, 2014	$0.20

STOCK_OPTIONS_Incentive_Stock_

STOCK OPTIONS - Incentive Stock Option Transactions (Details 1) (Incentive stock options, USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2014	Dec. 31, 2013
		Minimum	Minimum	Maximum	Maximum
Option/Warrant Shares	'	'	'	'	'
Outstanding, December 31, 2013	59,866,667	'	'	'	'
Granted	6,000,000	'	'	'	'
Exercised	-12,000,000	'	'	'	'
Expired/Returned	'	'	'	'	'
Outstanding, June 30, 2014	53,866,667	'	'	'	'
Exercisable, June 30, 2014	45,366,667	'	'	'	'
Weighted Average Remaining Life, Exercisable, June 30, 2014 (years)	'9 years 1 month 6 days	'	'	'	'
Exercise Price	'	'	'	'	'
Outstanding, December 31, 2013	'	$0.05	$0.05	$0.15	$0.15
Granted	$0.05	'	'	'	'
Exercised	$0.05	'	'	'	'
Expired/Returned	'	'	'	'	'
Outstanding, June 30, 2014	'	$0.05	$0.05	$0.15	$0.15
Exercisable, June 30, 2014	'	$0.05	'	$0.15	'
Weighted Average Exercise Price	'	'	'	'	'
Outstanding	$0.05	'	'	'	'
Granted	$0.01	'	'	'	'
Exercised	$0.01	'	'	'	'
Expired/Returned	'	'	'	'	'
Outstanding	$0.05	'	'	'	'
Weighted Average Remaining Life, Exercisable, June 30, 2014 (years)	$0.06	'	'	'	'

STOCK_OPTIONS_Detail_Textuals

STOCK OPTIONS (Detail Textuals)	Dec. 17, 2013	Dec. 31, 2000	Dec. 31, 2013	Jun. 30, 2014
	Stock option 2000 plan	Stock option 2000 plan	Stock option 2003 plan	Stock option 2003 plan
	Stock options	Stock options	Common Stock	Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Number of shares authorized to grant options	18,000,000	1,500,000	20,000,000	'
Number of option issued	'	'	'	23,725,996
Number of options available to be issued	'	'	'	14,274,004

STOCK_OPTIONS_Detail_Textuals_

STOCK OPTIONS (Detail Textuals 1) (Stock options, USD $)

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Mar. 31, 2013

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

22-Jan-13

22-Jan-13

22-Jan-13

22-Jan-13

22-Jan-13

22-Jan-13

22-Jan-13

22-Jan-13

25-Feb-13

25-Feb-13

25-Feb-13

25-Feb-13

25-Feb-13

25-Feb-13

13-Mar-13

13-Mar-13

13-Mar-13

13-Mar-13

13-Mar-13

13-Mar-13

4-May-13

4-May-13

4-May-13

4-May-13

4-May-13

30-Sep-13

30-Sep-13

30-Sep-13

30-Sep-13

30-Sep-13

30-Sep-13

30-Sep-13

2-Dec-13

2-Dec-13

2-Dec-13

28-Mar-14

Employee

Employee

Employee

Employee

Employee

Employee

Employee

Employee

Employee

Employee

Employee

Employee

Employee

Employee

Director

Director

Director

Director

Director

Director

Director

Director

Director

Director

Director

Director

Chief Operating Officer

Chief Operating Officer

Chief Operating Officer

Chief Operating Officer

Chief Operating Officer

Chief Operating Officer

Chief Financial Officer

Chief Financial Officer

Chief Financial Officer

Director

Options Vests Immediately

Option Vests One Year

Options Vested Year Two

Option Vests One Year

Options Vested Year Two

Options Vested Year Three

Options Vests Immediately

Vested on March 13, 2014

Options Vests Immediately

Vested after the first year

Vested after the first year

Vested at the end of 24 months

Maximum

Minimum

Vested at the end of 24 months

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of option issued

'

'

'

1,000,000

'

'

'

'

'

'

500,000

'

'

'

'

'

2,000,000

'

'

'

'

'

2,000,000

'

'

'

'

'

1,000,000

'

'

'

'

1,000,000

'

6,000,000

Exercisable common stock share price

'

'

'

$0.05

'

'

'

'

'

'

$0.05

'

'

'

'

'

$0.05

'

'

'

'

'

$0.05

'

'

'

'

'

$0.15

'

'

'

'

$0.15

'

$0.05

Term for options

'

'

'

'10 years

'

'

'

'

'

'

'10 years

'

'

'

'

'

'10 years

'

'

'

'

'

'10 years

'

'

'

'

'

'10 years

'

'

'

'

'10 years

'

'10 years

Fair value of options issued

'

'

'

$99,972

'

'

'

'

'

'

$89,998

'

'

'

'

'

$439,963

'

'

'

'

'

$460,000

'

'

'

'

'

$99,840

'

'

'

'

$79,994

'

$599,893

Fair value of option issued expensed immediately

'

'

'

25,000

'

'

'

'

'

'

'

'

'

'

'

'

219,982

'

'

'

'

'

230,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of options vested

'

'

'

'

'

250,000

250,000

500,000

'

'

'

200,000

200,000

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of option vested

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50.00%

50.00%

'

'

'

50.00%

50.00%

50.00%

'

'

'

50.00%

'

'

'

'

50.00%

'

Expected volatility

'

'

'

222.00%

'

'

'

'

'

'

259.00%

'

'

'

'

'

235.00%

'

'

'

'

'

235.00%

'

'

'

'

'

'

'

272.80%

268.40%

'

266.10%

'

229.00%

Risk-free interest rate

'

'

'

1.90%

'

'

'

'

'

'

1.90%

'

'

'

'

'

2.00%

'

'

'

'

'

1.78%

'

'

'

'

'

1.39%

'

'

'

'

2.64%

'

2.73%

Expected option life (in years)

'

'

'

'10 years

'

'

'

'

'

'

'10 years

'

'

'

'

'

'10 years

'

'

'

'

'

'10 years

'

'

'

'

'

'10 years

'

'

'

'

'10 years

'

'10 years

Method used to calculate the grant-date fair value of the warrants

'

'

'

'Black-Scholes option pricing model

'

'

'

'

'

'

'Black-Scholes option pricing model

'

'

'

'

'

'Black-Scholes option pricing model

'

'

'

'

'

'Black-Scholes option pricing model

'

'

'

'

'

'Black-Scholes option pricing model

'

'

'

'

'Black-Scholes option pricing model

'

'Black-Scholes option pricing model

Allocated share-based compensation expense

6,231

12,462

13,900

'

46,768

'

'

'

5,000

'

'

'

'

'

54,845

43,394

'

285,675

'

'

21,425

78,137

'

'

'

'

18,698

37,190

'

'

'

'

14,958

29,752

'

'

Stock based compensation reversed upon cancellation of stock options

'

'

'

'

'

'

'

'

'

$5,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

STOCK_OPTIONS_Detail_Textuals_1

STOCK OPTIONS (Detail Textuals 2) (Stock options, USD $)	0 Months Ended	1 Months Ended
	Feb. 07, 2014	Feb. 25, 2014
		Chief Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Stock option exercised share (in shares)	6,000,000	6,000,000
Closing price of share	$0.07	$0.06
Exercise price	$0.05	$0.05
Number of options received	6,000,000	6,000,000
Number of stock issued	1,714,285	1,000,000

OPERATING_LEASES_Details

OPERATING LEASES (Details) (USD $)	Jun. 30, 2014
Leases, Operating [Abstract]	'
2014	$36,468
2015	74,637
2016	31,605
Total	$142,710

OPERATING_LEASES_Detail_Textua

OPERATING LEASES (Detail Textuals) (General and administrative expense, USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
General and administrative expense	'	'	'	'
Schedule Of Operating Lease [Line Items]	'	'	'	'
Total rent expense under leases	$17,766	$12,344	$35,493	$18,344

RELATED_PARTY_TRANSACTIONS_Det

RELATED PARTY TRANSACTIONS (Detail Textuals) (Senior secured convertible notes payable, USD $)	Jun. 30, 2014
	Shareholder
Senior secured convertible notes payable	'
Debt Instrument [Line Items]	'
Number of shareholders	3
Convertible notes payable	$164,000
Amount of accrued interest owed by shareholders	$124,332

SUBSEQUENT_EVENTS_Detail_Textu

SUBSEQUENT EVENTS (Detail Textuals) (Subsequent Event, Verify Me, USD $)	1 Months Ended
In Millions, unless otherwise specified	Jul. 31, 2014
Subsequent Event | Verify Me	'
Subsequent Event [Line Items]	'
Duration of contract	'10 years
Value of contract	$7